Emergent BioSolutions Stock: Berger Montague Investigates Potential Securities Fraud Claims Against Emergent BioSolutions Inc. (EBS); Lead Plaintiff Deadline is June 18, 2021
Philadelphia, Pennsylvania--(Newsfile Corp. - May 13, 2021) - May 13, 2021 - Berger Montague announces its investigation into potential securities fraud claims against Emergent BioSolutions Inc. (NYSE: EBS) ("Emergent" or the "Company"). The Firm is investigating these claims on behalf of investors who purchased Emergent securities between July 6, 2020 and March 31, 2021 (the "Class Period").
If you purchased Emergent securities during the Class Period, would like to discuss Berger Montague's investigation, or have questions concerning your rights or interests, please contact attorneys Andrew Abramowitz at email@example.com or (215) 875-3015, or Donnell Much at firstname.lastname@example.org or (215) 875-4667, or contact us at www.bergermontague.com/emergent.
Whistleblowers: Persons with non-public information regarding Emergent are encouraged to confidentially assist Berger Montague's investigation or take advantage of the SEC Whistleblower program. Under this program, whistleblowers who provide original information may receive rewards totaling up to thirty percent (30%) of recoveries obtained by the SEC. For more information, contact us.
Emergent is a biopharmaceutical company that develops vaccines for infectious diseases. According to a recently filed lawsuit, the Company and senior management failed to disclose a history of manufacturing issues and quality control deficiencies at Emergent's Baltimore facility, and that longstanding contamination risks had resulted in a string of citations by the Food and Drug Administration.
On March 31, 2021, media reports revealed that Emergent "mixed up" ingredients for J&J's and AstraZeneca's Covid vaccines, which resulted in up to 15 million doses of J&J's vaccine being contaminated and rendered unusable. On this news, shares declined $14.29 - approximately 15% - over the next two trading days, from a closing price of $92.91 on March 31 to $78.62 on April 5.
Subsequent revelations followed. For instance, on April 6, 2021, the New York Times reported that "[p]reviously undisclosed internal documents and interviews with current and former federal officials and former company employees depict a factory operation that was ill-equipped to take on such a mammoth manufacturing task."
If you purchased Emergent securities during the Class Period, you may seek Court appointment as lead plaintiff to represent other injured investors in a class action. The lead plaintiff appointment deadline is June 18, 2021. You do not need to be a lead plaintiff to share in any potential Class recovery.
Berger Montague, with offices in Philadelphia, Minneapolis, Washington, D.C., and San Diego, has been a pioneer in securities class action litigation since its founding in 1970. Berger Montague has represented individual and institutional investors for over five decades and serves as lead counsel in courts throughout the United States.
Andrew Abramowitz, Senior Counsel
Donnell Much, Associate
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/83956